Randomized, controlled trial of acetazolamide and furosemide in posthemorrhagic ventricular dilation in infancy: Follow-up at 1 year

Pediatrics

Volumn 108, Issue 3, 2001, Pages 597-607

  Kennedy, Colin R ^a   Ayers, Sarah ^b   Campbell, Michael J ^c   Elbourne, Diane ^b,d   Hope, Peter ^e   Johnson, Ann ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acetazolamide; Furosemide; Hydrocephalus; Infancy; Intraventricular hemorrhage

Indexed keywords

ACETAZOLAMIDE; FUROSEMIDE;

ARTICLE; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN VENTRICLE DILATATION; BRAIN VENTRICLE PERITONEUM SHUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEMALE; HIGH RISK POPULATION; HUMAN; INFANT; INFANT DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NEUROLOGICAL COMPLICATION; OUTCOMES RESEARCH; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL;

ACETAZOLAMIDE; CEPHALOMETRY; CEREBRAL HEMORRHAGE; CEREBROSPINAL FLUID SHUNTS; DIURETICS; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; FUROSEMIDE; HUMANS; HYDROCEPHALUS; INFANT; LOGISTIC MODELS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034860485     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.108.3.597     Document Type: Article

References (32)

1. Long term developmental outcomes of low birthweight infants
2. Infantile hydrocephalus: Declining prevalence in preterm infants
3. Current gestational age-related incidence of major intraventricular hemorrhage
4. Trends in the incidence and severity of intraventricular haemorrhage
5. Randomised trial of early tapping in neonatal posthaemorrhagic ventricular dilatation
6. Randomised trial of early tapping in neonatal posthaemorrhagic ventricular dilatation: Results at 30 months
7. Neurosurgical management of hydrocephalus
8. Neuroendoscopic third ventriculostomy in patients less than one year old
9. Failure of daily lumbar punctures to prevent the development of hydrocephalus following intraventricular hemorrhage
10. Serial lumbar punctures in prevention of posthemorrhagic hydrocephalus in preterm infants
11. Phase 1 study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus
12. Medical management of hydrocephalus
13. Isosorbide in the management of infantile hydrocephalus
14. Isosorbide in the medical management of hydrocephalus in children with myelodysplasia
15. Treatment of hydrocephalus with acetazolamide
16. Medical management of hydrocephalus with acetazolamide and frusemide
17. Management of hydrocephalus in infancy: Use of acetazolamide and furosemide to avoid cerebrospinal fluid shunts
18. International randomised controlled trial of acetazolamide and furosemide in posthaemorrhagic ventricular dilatation in infancy
19. Measurement of the growth of the lateral ventricles in preterm infants with realtime ultrasound
20. Comparison of Vineland Adaptive Behaviour Scales - Survey form age equivalent and standard score with the Bayley Mental Development Index
21. Trials stopped early: Too good to be true?
22. Acetazolamide in posthaemorrhagic ventricular dilatation
23. Acute effects of acetazolamide on cerebral blood flow velocity and pCO2 in the newborn infant
24. Infantile hydrocephalus epidemiology: An indicator of enhanced survival
25. The changing epidemiology of cerebral palsy
26. Intraventricular hemorrhage in preterm infants: Declining incidence in the 1980s
27. Cerebrospinal fluid plasminogen activator inhibitor-1: A prognostic factor in posthaemorrhagic hydrocephalus
28. Lysis of intraventricular clot with urokinase in an animal model. Part 3. Effects of intraventricular urokinase on clot lysis and posthaemorrhagic hydrocephalus
29. Subacute hydrocephalus after experimental subarachnoid haemorrhage: Its prevention by intrathecal fibrinolysis with recombinant tissue plasminogen activator